Both formulations are approved for people with obesity (BMI greater than 30) or excess weight (BMI greater than 27) who also have at least one other weight-related health condition, such as type 2 diabetes, high blood pressure, or high cholesterol
GLP-1RA, as a glucose reducing medication, can reduce the glycation process and the production of AGEs
Cutis, 115 (1), 713
albicans infection rates have been reported in CDI patients, suggesting that C
However, they differ in a key way: tirzepatide is a dual agonist (GLP-1 and GIP), while retatrutide is a triple agonist (GLP-1, GIP, and GCG)
Thats why the product labels recommend stopping GLP-1s at least two months before conception